Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: A new molecule

Shlomo Yehuda

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Tyrosine is unable to cross the blood-brain barrier and is therefore unable to improve the status of brain dopamine (DA) and to provide relief for patients with Parkinson's disease (PD) or other DA-insufficient disorders. We report the creation of an amide bond molecule [N-(α-linolenoyl)tyrosine (NLT)] that combines tyrosine with a fatty acid mixture. NLT significantly improves the rotational behavior of rats [following unilateral striatal lesions (as a model for Parkinson's)] and overcomes the exaggerated eye-blinking induced by a potent DA-depleting agent (as a model for essential blepharospasm). These results are supported by the finding that NLT's mode of action, in striatum, is the same as the mode of action of D-amphetamine. They both induce an increase in the DA level, DA turnover and release.

Original languageEnglish
Pages (from-to)7-11
Number of pages5
JournalPharmacology Biochemistry and Behavior
Issue number1-2
StatePublished - May 2002


  • Amide bond
  • Animal model
  • Dopamine
  • Parkinson's disease
  • Tyrosine
  • α-Linolenic acid


Dive into the research topics of 'Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: A new molecule'. Together they form a unique fingerprint.

Cite this